Evidence map›Paper›PMID 42603160›Full record

ArticleJACC. Case reports2026

Percutaneous Tricuspid Valve-in-Valve Implantation With Melon Seeding During Deployment.

Alexander M Sellers, Shreyas Ravat, Jayme Bennetts, Ross Roberts-Thomson, Ehsan Khan, Jean Engela, Jayne Langran, Ajay R Sinhal

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alexander M SellersDepartment of Cardiology, Southern Adelaide Local Health Network, Adelaide, Australia; Faculty of Health Sciences, School of Medicine, Flinders University, Adelaide, Australia. Electronic address: alexsellers1992@gmail.com.
Shreyas RavatDepartment of Cardiology, Southern Adelaide Local Health Network, Adelaide, Australia.
Jayme BennettsFaculty of Health Sciences, School of Medicine, Flinders University, Adelaide, Australia; Department of Cardiothoracic Surgery, Adelaide, South Australia, Australia.
Ross Roberts-ThomsonDepartment of Cardiology, Central Adelaide Local Health Network, Adelaide, Australia; College of Health, Adelaide University, Adelaide, Australia.
Ehsan KhanDepartment of Cardiology, Southern Adelaide Local Health Network, Adelaide, Australia; Faculty of Health Sciences, School of Medicine, Flinders University, Adelaide, Australia.
Jean EngelaDivision of Medical Imaging, Southern Adelaide Local Health Network, Adelaide, Australia.
Jayne LangranDepartment of Cardiology, Southern Adelaide Local Health Network, Adelaide, Australia.
Ajay R SinhalDepartment of Cardiology, Southern Adelaide Local Health Network, Adelaide, Australia; Faculty of Health Sciences, School of Medicine, Flinders University, Adelaide, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBioprosthetic tricuspid valves are prone to structural deterioration over time. In patients with multiple prior sternotomies and functioning left-sided prostheses, repeat surgery may carry prohibitive risk, prompting consideration of transcatheter alternatives. CASE SUMMARY: A 42-year-old patient with rheumatic heart disease and a history of 3 prior sternotomies for mitral, aortic, and tricuspid valve replacement presented with recurrent admissions for diuretic-resistant right heart failure complicated by congestive hepatopathy (Child-Pugh B cirrhosis). Imaging demonstrated severe stenosis of a bioprosthetic tricuspid valve, with preserved left-sided valve function. The patient underwent successful percutaneous tricuspid valve-in-valve implantation, resulting in marked symptomatic improvement and significant reduction in transvalvular gradients on echocardiography. DISCUSSION: Current guidelines support reintervention for symptomatic bioprosthetic valve dysfunction. In high surgical risk patients, percutaneous tricuspid valve-in-valve implantation represents an effective and less invasive alternative to repeat surgery. TAKE-HOME MESSAGE: Percutaneous tricuspid valve-in-valve replacement is a viable therapeutic option for failed tricuspid bioprostheses in carefully selected high-risk patients.

Indexed as

rheumatic heart diseasetricuspid valvevalve replacement

Identifiers

PMID42603160
PMCPMC13643540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.